This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
AbbVie Inc’s all-oral, 12-week hepatitis C therapy cured 96 percent of 394 Genotype 1 patients, half of whom were previous `null responders` to standard treatment of pegylated interferon-ribavirin. More information below…
from Yahoo HERE
http://ca.news.yahoo.com/abbvie-says-96-percent-patients-oral-hepatitis-c-133448285–finance.html
and from AbbVie HERE
http://abbvie.mediaroom.com/2013-12-10-AbbVie-Demonstrates-96-percent-SVR-12-in-its-Phase-III-Study-of-Treatment-Experienced-Patients-with-Genotype-1-Hepatitis-C